Company / EPS (Basic)
Charles River Laboratories EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$2.91
FY2025
5-year range
-$2.91 / $9.57
FY2021-FY2025
Trend
-130.4%
vs FY2024
Sector context
#145 of 160
Health Care
What the data says
Among 160 Health Care companies, Charles River Laboratories is in the bottom 9% for eps (basic). EPS (Basic) has fluctuated over the past 10 years, ranging from $-2.91 in FY2025 to $9.57 in FY2024.
Based on SEC 10-K filings.
-2.91 in FY2025.
Declined from $7.77 to $-2.91 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 160This company -$2.91 Sector average $2.36
▼
-223.1% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) decreased 130.4% year-over-year.
- Ranks #145 out of 160 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.91 | -130.4% |
| FY2024 | $9.57 | +23.2% |
| FY2023 | $7.77 | +5.7% |
| FY2022 | $7.35 | +42.2% |
| FY2021 | $5.17 | +9.5% |
| FY2020 | $4.72 | +81.5% |
| FY2019 | $2.60 | -21.0% |
| FY2018 | $3.29 | +2.5% |
| FY2017 | $3.21 | +18.0% |
| FY2016 | $2.72 | +26.5% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026